Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation

The majority of patients with acute myeloid leukemia (AML) with the NPM1 mutation achieve remission with intensive chemotherapy. However, many patients subsequently relapse, which occurs frequently within the first 2–3 years after therapy, while late relapse after more than 10 years is rare and can...

Descripción completa

Detalles Bibliográficos
Autores principales: Braune, Jan, Rieger, Kathrin, Blau, Olga, Keller, Ulrich, Bullinger, Lars, Krönke, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812588/
https://www.ncbi.nlm.nih.gov/pubmed/36619478
http://dx.doi.org/10.1155/2022/3317936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812588/
https://www.ncbi.nlm.nih.gov/pubmed/36619478
http://dx.doi.org/10.1155/2022/3317936

Ejemplares similares